Quality of life assessments in Major Depressive Disorder: a review of the literature

被引:226
作者
Papakostas, GI [1 ]
Petersen, T [1 ]
Mahal, Y [1 ]
Mischoulon, D [1 ]
Nierenberg, AA [1 ]
Fava, M [1 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA
关键词
quality of life; major depression;
D O I
10.1016/j.genhosppsych.2003.07.004
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
According to the DSM-IV classification, a diagnosis of Major Depressive Disorder (MDD) is possible only when there is evidence of significant inference with functioning. However, despite the high prevalence of MDD in the general population [1], it is uncommon for clinicians to assess overall functioning in a systematic way before making such diagnosis. An important correlate of functioning is quality of life, which is typically defined as "patients' own assessments of how they feel about what they have, how they are functioning, and their ability to derive pleasure from their life activities" [2]. In the present article, we review studies focusing on the relationship between depression and quality of life, particularly focusing on the impact of the treatment of depression on quality of life. Studies focusing on the quality of life in MDD are reviewed. Candidate studies published between 1970 and recently were initially identified by Pubmed and Ovid search cross-referencing the terms "quality of life," "psychosocial functioning" with "major depression" and "treatment." A number of studies report poorer quality of life in MDD patients compared to controls. Several studies also report an improvement in quality of life measures during various phases of treatment with antidepressants and/or psychotherapy. However, trials comparing the role of newer psychopharmacologic agents in the acute phase of treatment, and the role of newer psychotherapies in the continuation and maintenance phases of treatment in restoring psychosocial functioning and improving the quality of life in MDD are lacking. Exploring the impact of these modalities on psychosocial function and quality of life in MDD are necessary to help translate clinical response into restoration of psychosocial function and to thus further improve the standard of care. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:13 / 17
页数:5
相关论文
共 63 条
[1]   Sertraline versus paroxetine in major depression:: Clinical outcome after six months of continuous therapy [J].
Åberg-Wistedt, A ;
Ågren, H ;
Ekselius, L ;
Bengtson, F ;
Åkerblad, AC .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (06) :645-652
[2]   Personality disorder symptoms predict declines in global functioning and quality of life in elderly depressed patients [J].
Abrams, RC ;
Alexopoulos, GS ;
Spielman, LA ;
Klausner, E ;
Kakuma, T .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2001, 9 (01) :67-71
[3]   Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression [J].
Andreoli, V ;
Caillard, V ;
Deo, RS ;
Rybakowski, JK ;
Versiani, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (04) :393-399
[4]  
Booth BM, 1997, PSYCHOPHARMACOL BULL, V33, P653
[5]   DEPRESSION, DISABILITY DAYS, AND DAYS LOST FROM WORK IN A PROSPECTIVE EPIDEMIOLOGIC SURVEY [J].
BROADHEAD, WE ;
BLAZER, DG ;
GEORGE, LK ;
CHIU, KT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (19) :2524-2528
[6]   A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine [J].
Carpenter, LL ;
Yasmin, S ;
Price, LH .
BIOLOGICAL PSYCHIATRY, 2002, 51 (02) :183-188
[7]   Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression [J].
Dam, J ;
Ryde, L ;
Svejso, J ;
Lauge, N ;
Lauritsen, B ;
Bech, P .
PHARMACOPSYCHIATRY, 1998, 31 (02) :48-54
[8]   IMPAIRMENT OF WORK AND LEISURE IN DEPRESSED OUTPATIENTS - A PRELIMINARY COMMUNICATION [J].
DELISIO, G ;
MAREMMANI, I ;
PERUGI, G ;
CASSANO, GB ;
DELTITO, J ;
AKISKAL, HS .
JOURNAL OF AFFECTIVE DISORDERS, 1986, 10 (02) :79-84
[9]  
Doraiswamy PM, 2001, AM J GERIAT PSYCHIAT, V9, P423
[10]  
EATON WW, 1981, PUBLIC HEALTH REP, V96, P319